Keensight Capital

Our role

Our Direct Lending team is pleased to be providing senior debt facilities on a sole lender basis to support Keensight Capital with its investment in Bedfont Scientific, a leading global innovator in non-invasive breath diagnostic and monitoring technologies.

We worked collaboratively with Keensight to arrange a competitive, flexible financing package and deliver financing certainty to Keensight in a short timeframe.

We are delighted to support the Keensight team, with the deal reflecting Direct Lending’s first transaction with such a highly regarded investor. We look forward to building a long-term partnership with Keensight, alongside working closely with the management team at Bedfont.  

About Keensight Capital

Keensight Capital is a leading European growth buyout investor, specialising in partnering with entrepreneurs to support profitable, high-growth companies in Healthcare and Technology.

Keensight operates from offices across the globe including London, Paris and the US, and currently has more than €6bn of AUM as at Jun-25.

About Bedfont Scientific

Bedfont Scientific is a UK-based innovator in non-invasive breath analysis and monitoring technologies, with a 50-year track record of developing pioneering medical devices.

Its flagship products, including NObreath, Smokerlyzer, and Gastrolyzer, are distributed in over 70 countries through a global network of partners, addressing critical healthcare needs in respiratory health, smoking cessation, and gastrointestinal diagnostics.